235,062 Shares in Integra LifeSciences Holdings Co. (NASDAQ:IART) Acquired by Connor Clark & Lunn Investment Management Ltd.

Connor Clark & Lunn Investment Management Ltd. acquired a new position in shares of Integra LifeSciences Holdings Co. (NASDAQ:IART - Free Report) in the 3rd quarter, according to its most recent 13F filing with the SEC. The fund acquired 235,062 shares of the life sciences company's stock, valued at approximately $4,271,000. Connor Clark & Lunn Investment Management Ltd. owned about 0.30% of Integra LifeSciences at the end of the most recent reporting period.

A number of other institutional investors and hedge funds have also recently bought and sold shares of the stock. Cooke & Bieler LP grew its stake in Integra LifeSciences by 12.4% in the 2nd quarter. Cooke & Bieler LP now owns 3,514,281 shares of the life sciences company's stock worth $102,406,000 after acquiring an additional 388,710 shares during the period. Dimensional Fund Advisors LP grew its position in shares of Integra LifeSciences by 0.7% in the second quarter. Dimensional Fund Advisors LP now owns 1,785,009 shares of the life sciences company's stock valued at $52,014,000 after purchasing an additional 12,766 shares during the period. D. E. Shaw & Co. Inc. increased its stake in Integra LifeSciences by 64.6% in the second quarter. D. E. Shaw & Co. Inc. now owns 855,352 shares of the life sciences company's stock valued at $24,925,000 after purchasing an additional 335,557 shares during the last quarter. AQR Capital Management LLC lifted its position in Integra LifeSciences by 90.9% during the second quarter. AQR Capital Management LLC now owns 611,798 shares of the life sciences company's stock worth $17,436,000 after buying an additional 291,326 shares during the period. Finally, Leeward Investments LLC MA lifted its position in Integra LifeSciences by 32.7% during the second quarter. Leeward Investments LLC MA now owns 600,208 shares of the life sciences company's stock worth $17,490,000 after buying an additional 147,770 shares during the period. Hedge funds and other institutional investors own 84.78% of the company's stock.

Analyst Ratings Changes

IART has been the subject of a number of research analyst reports. Truist Financial dropped their price objective on shares of Integra LifeSciences from $26.00 to $21.00 and set a "hold" rating for the company in a research note on Monday, October 14th. BTIG Research raised Integra LifeSciences from a "sell" rating to a "neutral" rating in a research note on Monday, October 7th. JMP Securities dropped their target price on shares of Integra LifeSciences from $40.00 to $35.00 and set a "market outperform" rating for the company in a research report on Tuesday, July 30th. Citigroup boosted their price objective on shares of Integra LifeSciences from $16.00 to $22.00 and gave the stock a "sell" rating in a research note on Tuesday, November 5th. Finally, Bank of America cut their price objective on shares of Integra LifeSciences from $26.00 to $18.00 and set an "underperform" rating on the stock in a report on Monday, October 7th. Three investment analysts have rated the stock with a sell rating, five have given a hold rating and one has issued a buy rating to the stock. According to MarketBeat, Integra LifeSciences currently has an average rating of "Hold" and an average price target of $24.00.

Integra LifeSciences Stock Performance

Shares of NASDAQ:IART traded up $0.58 on Friday, reaching $23.58. 570,985 shares of the company's stock were exchanged, compared to its average volume of 1,165,765. The business's 50-day moving average is $20.08 and its two-hundred day moving average is $24.02. The company has a quick ratio of 0.73, a current ratio of 1.20 and a debt-to-equity ratio of 0.79. Integra LifeSciences Holdings Co. has a fifty-two week low of $16.81 and a fifty-two week high of $45.42. The firm has a market capitalization of $1.82 billion, a price-to-earnings ratio of -262.00, a PEG ratio of 0.78 and a beta of 1.08.

Integra LifeSciences (NASDAQ:IART - Get Free Report) last issued its earnings results on Monday, November 4th. The life sciences company reported $0.41 earnings per share (EPS) for the quarter, topping analysts' consensus estimates of $0.39 by $0.02. The firm had revenue of $380.80 million for the quarter, compared to analysts' expectations of $375.81 million. Integra LifeSciences had a negative net margin of 0.42% and a positive return on equity of 12.35%. Integra LifeSciences's revenue was down .4% on a year-over-year basis. During the same quarter last year, the company posted $0.76 earnings per share. As a group, equities research analysts forecast that Integra LifeSciences Holdings Co. will post 2.45 EPS for the current year.

Integra LifeSciences Profile

Integra LifeSciences Holdings Corporation manufactures and sells surgical instruments, neurosurgical products, and wound care products for use in neurosurgery, neurocritical care, and otolaryngology. It operates in two segments, Codman Specialty Surgical and Tissue Technologies. The company offers neurosurgery and neuro critical care products, including tissue ablation equipment, dural repair products, cerebral spinal fluid management devices, intracranial monitoring equipment, and cranial stabilization equipment; and surgical headlamps and instrumentation, as well as after-market services.